NCT00743379 - Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

March 31, 2014

Conditions

Non-Small Cell Lung CancerProstate CancerPancreatic Cancer

Interventions

DRUG

TH-302

TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.

Trial Locations (11)

27710

Duke University Medical Center, Durham

37203

Sarah Cannon Research Institute, Nashville

46202

Indiana University Cancer Center, Indianapolis

48201

Karmanos Cancer Institute, Detroit

53792

University of Wisconsin, Madison

55905

Mayo Clinic, Rochester

71130

LSU Health Sciences Center, Shreveport

78229

UT Health Science Center, San Antonio

85259

Mayo Clinic Cancer Center, Scottsdale

85260

Premiere Oncology of Arizona, Scottsdale

98405

Northwest Medical Specialties, Tacoma